drugset / Trial / NCT00006046
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced colorectal cancer.
Timeline
- Start
- 2000-07-12
- Primary completion
- 2001-10-05
- Completion
- 2002-09-24
Outcome
Outcome not reported
Stopped (Enrollment): “poor recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hu3S193 | Monoclonal antibody | 10 mg/m2 | Intravenous |
| Subject | hu3S193 | Monoclonal antibody | 25 mg/m2 | Intravenous |
| Subject | hu3S193 | Monoclonal antibody | 50 mg/m2 | Intravenous |
| Subject | hu3S193 | Monoclonal antibody | 100 mg/m2 | Intravenous |
| Subject | hu3S193 | Monoclonal antibody | 200 mg/m2 | Intravenous |